630
Participants
Start Date
January 24, 2019
Primary Completion Date
September 28, 2020
Study Completion Date
September 28, 2020
ASP3772
Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly
PCV13
Participants received a single dose of PCV13 intramuscularly.
PPSV23
Participants received a single dose of PPSV23 intramuscularly.
United Medical Associates, Binghamton
CRA of Tidewater Inc, Norfolk
PMG Research of Winston-Salem, LLC, Winston-Salem
PMG Research of Raleigh, Raleigh
PMG Research of Hickory, LLC, Rocky Mount
Wilmington Health, Wilmington
Piedmont HealthCare, PA, Statesville
Meridian Clinical Research, Savannah
Research Centers of America, Hollywood
PMG Research, Knoxville
PMG Research, Knoxville
Sundance Clinical Research, St Louis
Meridian Clinical Research, Norfolk
Tekton Research - George Town, Yukon
Healthcare Associatiates of Texas, McKinney
Texas Healthcare, PLLC, Fort Worth
Benchmark Research, Fort Worth
Benchmark Research, San Angelo
Texas Center for Drug Development, Houston
Martin Diagnostic Clinic, Tomball
DM Clinical Research, Pearland
Clinical Trials of Texas, San Antonio
Advanced Clinical Research Institute, Cedar Park
Artemis Institute, San Marcos
Artemis Institute, San Diego
Advanced Clinical Research-Rancho Paseo, Banning
Lead Sponsor
Collaborators (1)
Affinivax, Inc.
INDUSTRY
GlaxoSmithKline
INDUSTRY